LILRB1-directed CAR-T cells

LILRB1-directed CAR-T cells are investigational cell therapies in which patient or donor T lymphocytes are genetically engineered to express a chimeric antigen receptor (CAR) that targets leukocyte immunoglobulin-like receptor B1 (LILRB1, also known as CD85j). LILRB1 is an immune inhibitory receptor predominantly expressed on monocytes, B cells, and some other immune cells, and it is stably present on malignant cells in B-cell acute lymphoblastic leukemia (B-ALL), B-cell non-Hodgkin lymphoma (B-NHL), and monocytic acute myeloid leukemia (AML), including in cases resistant to CD19 CAR-T therapy. The engineered CAR typically contains a single-chain variable fragment (scFv) derived from anti-LILRB1 monoclonal antibodies, joined to a second-generation intracellular signaling domain (including CD8 hinge and 4-1BB-CD3zeta signaling motifs), enabling the T cells to recognize and kill LILRB1-expressing tumor cells. In preclinical models, LILRB1-directed CAR-T cells have demonstrated antigen-specific cytotoxicity against B-ALL, B-NHL, and AML, including tumors resistant to prior CD19 CAR-T or CD20/CD19-based therapies, and have shown efficacy in vitro and in vivo xenograft studies[1][3][4].

Other names

LILRB1 CAR-T cellsLILRB-1 CAR-T cellsLILRB 1 CAR-T cellsLILRB1-targeting CAR-T cellsLILRB-1-targeting CAR-T cellsLILRB 1-targeting CAR-T cellsLeukocyte immunoglobulin-like receptor B1-directed CAR-T cellsCD85j-directed CAR-T cellsCD-85j-directed CAR-T cellsCD 85j-directed CAR-T cells